Amifostine is under clinical development by Original BioMedicals and currently in Phase I for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome). According to GlobalData, Phase I drugs for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Amifostine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Amifostine overview
Amifostine is under development for the treatment of acute radiation syndrome. The drug candidate is administered through intravenous route. The drug candidate is developed based on chelating-complex micelle (CCM) which is composed of polyethylene glycol micelle with a metal moiety in it that combines the chelates with blocking copolymers to form reversible bonds.
Original BioMedicals overview
Original BioMedicals (OBM) is a biotechnology company that develops new drug delivering systems to deal with unmet clinical needs in the therapeutic areas of oncology, hematology and immunology. The company’s pipeline products include A01, A02 and P01. Its pipeline product OBM-A01 is used for the treatment of acute radiation syndrome; OBM-A02 used in cancer adjuvant therapy which improves the side effects of chemotherapy; and (P01) GLP-1 CCM for the treatment of Type 2 diabetes. OBM provides technologies such as Chelating-Complex Micelle and Trigger Release Technology. Its Trigger Release Technology is used in various applications such as rapid trigger release, slow trigger release and trigger-slow (stop) release. The company has partnerships with pharma and biotech companies. OBM is headquartered in Tainan, Taiwan.
For a complete picture of Amifostine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
